710583Novel, multi-action payloads for antibody drug conjugatesClosedGRD Proof of ConceptInnovate UKAntibody drug conjugates (ADCs) are a new wave of targeted cancer therapies that promise dramatically increased survival with significantly lower side effects. Potent toxic “payloads” are attached to tumour-cell specific targeting vehicles called antibodies. This is an early technology with only 2 approved products. There is still a need to develop improved payloads, especially ones that do not succumb to drug resistance in patients and also ones that can potentially kill the dormant cancer stem cells that reside deep within tumours. PhotoBiotics has some experience working with a novel class of payloads that works by many different and independent cellular mechanisms, thereby reducing the likelihood that a cell can mutate and become resistant and increasing the chance of killing dormant cancer cells. In this application, PhotoBiotics will use state-of-the-art established as well as novel strategies to make and evaluate more potent payloads in a form that can be linked onto targeting antibodies to generate significantly better ADCs than are in the clinic today.